skip to main content
Lingue:

Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications

Kopchick, John J ; List, Edward O ; Kelder, Bruce ; Gosney, Elahu S ; Berryman, Darlene E

Molecular and Cellular Endocrinology, 05 April 2014, Vol.386(1-2), pp.34-45 [Rivista Peer Reviewed]

Fulltext disponibile

Citazioni Citato da
  • Titolo:
    Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications
  • Autore: Kopchick, John J ; List, Edward O ; Kelder, Bruce ; Gosney, Elahu S ; Berryman, Darlene E
  • Note di contenuto: •Exess GH leads to poor health outcomes.•Removal of GH action is associated with resistance to diabetes and cancer.•The GHA was discovered using transgenic mice that express mutated GH genes.•Somavert® (pegvisomant for injection) is an approved drug for acromegaly.•GHA may have applications for selected cancer indications. The discovery of a growth hormone receptor antagonist (GHA) was initially established via expression of mutated GH genes in transgenic mice. Following this discovery, development of the compound resulted in a drug termed pegvisomant, which has been approved for use in patients with acromegaly. Pegvisomant treatment in a dose dependent manner results in normalization of IGF-1 levels in most patients. Thus, it is a very efficacious and safe drug. Since the GH/IGF-1 axis has been implicated in the progression of several types of cancers, many have suggested the use of pegvisomant as an anti-cancer therapeutic. In this manuscript, we will review...
  • Fa parte di: Molecular and Cellular Endocrinology, 05 April 2014, Vol.386(1-2), pp.34-45
  • Soggetti: Growth Hormone Receptor Antagonist (Gha) ; Gha ; Somavert ; Pegvisomont ; Ghr−/− Mice ; Faghrko ; Gh ; Gha ; Tnf-Α ; Il-6 ; IGF-1 ; Ghr−/− ; Mck ; Faghrko ; Wat
  • Lingua: Inglese
  • Tipo: Articolo
  • Identificativo: ISSN: 0303-7207 ; E-ISSN: 1872-8057 ; DOI: 10.1016/j.mce.2013.09.004

Ricerca in corso nelle risorse remote ...